
|Articles|September 16, 2015
Global Ischemic Heart Disease Market to Grow at 3.61% CAGR to 2019
September 17, 2015.
Advertisement
The global ischemic heart disease (IHD) drugs market is to grow at a CAGR of 3.61% during 2014-2019, according to a
According to the report, the high prevalence of chronic conditions such as hypertension, diabetes, and cholesterol levels are leading to an increase in cardiovascular diseases (CVDs). People with diabetes are three to four times more likely to develop CVDs than people without diabetes.
AstraZeneca, Bayer, Eli Lilly, Novartis, Pfizer, and Sanofi will dominate the market, states the report, although the availability of effective surgical treatments and the use of catheter based interventions will pose a challenge to market growth.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Novartis to Layoff 322 NJ Employees: Report
2
Launch is Just the Beginning: Rare Disease Care Requires Durability
3
Pharma M&A Roundup: Chemomab Therapeutics Enters Merger Agreement with Scipher Medicine, Teva and Polpharma Biologics Enter Global Licensing Agreement
4
“AI as Reinvention”: Transforming the Business of Medicine
5



